UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Initial Programs In Cognitive Impairment In Schizophrenia, Post-Operative Cognitive Decline

Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.   

Emerging Company Profile: Monument Therapeutics
Spinout has access to vast library of validated CNS biomarkers created by its parent • Source: Alamy

Recently spun out from UK-based Cambridge Cognition Holdings plc with 15-months’ worth of working seed capital, CNS-focused Monument Therapeutics is now working to put two repurposed and reformulated compounds into the clinic next year, one to treat cognitive impairment in schizophrenia and another for post-operative cognitive dysfunction, or POCD, a condition arising from major surgery.

Monument raised £2.6m in seed funding in June to further its development strategy of leveraging digital assessments of cognition to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category